Showing 3441-3450 of 6035 results for "".
- Study Shows Efficient AAV Delivery of Large Genes Using ViGeneron's REVeRT Technologyhttps://modernod.com/news/study-shows-efficient-aav-delivery-of-large-genes-using-vigenerons-revert-technology-1/2481913/ViGeneron announced a peer-reviewed publication in
- The Vision Council and RX Announce New Host City for Vision Expo East 2025 and Future Yearshttps://modernod.com/news/the-vision-council-and-rx-announce-new-host-city-for-vision-expo-east-2025-future-years/2481903/The Vision Council and RX, co-owners of Vision Expo, announced that Vision Expo East 2025 will take place in Orlando, Florida at the Orange County Convention Center (OCCC) February 19-22, 2025. Vision Expo East’s final show in New York will occur March 14-17, 2024. Vision Exp
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place
- Oculis Appoints Rebecca Weil, PhD, as Chief Commercial Officer as it Enters Pre-Commercial Phasehttps://modernod.com/news/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer-as-it-enters-pre-commercial-phase/2481823/Oculis announced the appointment of Rebecca Weil, PhD, to the role of Chief Commercial Officer. In this role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for US and globally, and building the required commercial infrastructure to bring all of
- MSU Researchers Discover Link Between Cholesterol and Diabetic Retinopathyhttps://modernod.com/news/msu-researchers-discover-link-between-cholesterol-and-diabetic-retinopathy/2481822/Research led by Michigan State and other universities found that diabetes, age-related health conditions, and other metabolic disorders can lead to a buildup of cholesterol in the retina. This tends to crystalize and contribute to the development of diabetic retinopathy. Cryst
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Scientists Develop Therapeutic Model for Potentially Treating Incurable Eye Diseaseshttps://modernod.com/news/scientists-develop-therapeutic-model-for-potentially-treating-incurable-eye-diseases/2481794/Researchers have successfully transplanted human microglia cells into mouse retina to create a model that could be used to test new treatments for retinal and central nervous system diseases, according to not-for-profit eLife. Microglia are the innate immune cells of the cent
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Regeneron Expects FDA Decision on High-Dose Aflibercept in Third Quarterhttps://modernod.com/news/regeneron-expects-fda-decision-on-high-dose-eylea-in-third-quarter/2481766/During its second quarter conference call, Regeneron said it anticipates the FDA will take action on its biologics license application (BLA) for high-dose aflibercept during the third quarter. In June, citing "an ongoing review of inspection findings at a third-party filler,"
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107https://modernod.com/news/asclepix-therapeutics-raises-10-million-to-advance-phase-12a-clinical-study-of-axt107/2481749/AsclepiX Therapeutics announced that it has secured a $10 million Series A-3 financing to advance clinical development of its lead candidate, AXT107 (gersizangitide), in patients with wet AMD. “With the completion of this round, we are excited to embark into the next phase of